1. Home
  2. KTTA vs REFR Comparison

KTTA vs REFR Comparison

Compare KTTA & REFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

HOLD

Current Price

$0.54

Market Cap

23.2M

Sector

Health Care

ML Signal

HOLD

Logo Research Frontiers Incorporated

REFR

Research Frontiers Incorporated

N/A

Current Price

$0.48

Market Cap

20.9M

Sector

Miscellaneous

ML Signal

N/A

Company Overview

Basic Information
Metric
KTTA
REFR
Founded
2020
1965
Country
United States
United States
Employees
5
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Multi-Sector Companies
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
23.2M
20.9M
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
KTTA
REFR
Price
$0.54
$0.48
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
436.1K
30.4K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,488,642.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.55
52 Week High
$2.06
$2.70

Technical Indicators

Market Signals
Indicator
KTTA
REFR
Relative Strength Index (RSI) 35.96 19.83
Support Level $0.49 N/A
Resistance Level $0.76 $0.83
Average True Range (ATR) 0.05 0.06
MACD 0.00 -0.01
Stochastic Oscillator 37.62 2.83

Price Performance

Historical Comparison
KTTA
REFR

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

About REFR Research Frontiers Incorporated

Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.

Share on Social Networks: